LX2020 — Regulatory decision
2026
Regulatory engagement with the FDA expected in 2026Source filing
LXEO biotech catalysts & pipeline
LEXEO THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
LX2020 — Full data
Q4 2026
12-month data update for all high dose participants in Q4 2026Source filing
next FA development candidate — IND submission
2027
The Company expects to provide a program prioritization update in early 2027 and submit an IND for its next FA development candidate in 2027.Source filing
LX2006 — Topline data
2H 2027
SUNRISE-FA 2 pivotal study continues enrollment and remains the company's top priority development program;topline data on track for 2H 2027Source filing
LX2006 — NDA/BLA submission
H1 2028
Potential BLA submission under accelerated approval pathway in first half of 2028Source filing